Achieve Life Sciences (ACHV) Debt to Equity (2016 - 2025)

Achieve Life Sciences (ACHV) recorded quarterly Debt to Equity of $0.17 in Q4 2025, up 380.59% on a QoQ basis from $0.04 in Q3 2025.

Achieve Life Sciences (ACHV) Debt to Equity (2016 - 2025) Analysis & Trends

Achieve Life Sciences has disclosed Debt to Equity across 5 years of filings, most recently posting $0.17 for Q4 2025.

Quarterly Debt to Equity changed N/A year-over-year to $0.17 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $0.17 (changed N/A YoY) and the FY2025 annual result came in at $0.17, changed N/A from the prior year.
Debt to Equity climbed to $0.17 in Q4 2025, from $0.04 in the prior quarter.
Over five years, Debt to Equity peaked at $36.95 in Q1 2023 and troughed at -$0.36 in Q4 2023.
A 4-year average of $4.38 and a median of $0.17 in 2025 frame the typical range for Debt to Equity.
Annual changes were most pronounced in 2023 — Debt to Equity sank 118.84% — and 2025, when it plunged 66.49%.
Tracing ACHV's Debt to Equity over 4 years: stood at $1.94 in 2022, then sank by 118.84% to -$0.36 in 2023, then jumped by 157.1% to $0.21 in 2024, then decreased by 17.32% to $0.17 in 2025.
Business Quant data shows ACHV's Debt to Equity at $0.17 in Q4 2025, $0.04 in Q3 2025, and $0.03 in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn	0.32
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn	-
9	Abivax	91.71 Bn	91.71 Bn	-	-
10	Achieve Life Sciences	93.71 Mn	63.22 Mn	-	-

Download Data